Form 4 holding
Director
Tempus AI, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 31,094
- Estimated value
- $1,349,479
- Report date
- 03 Aug 2026
- Price
- $43.40
- Ownership
- Direct
David R. Epstein
Insider Reports History
- Reporting-owner location
- New York, NY
- Latest reporting-owner signature
-
/s/ Andrew Polovin, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for David R. Epstein
Form 4 holding
Director
Axcella Health Inc.
- Security class
- Common Stock
- Shares / value
- 209,756
- Estimated value
- $121,658
- Report date
- 19 May 2022
- Price
- $0.5800
- Ownership
- Direct
Form 4 holding
Director
Evelo Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 93,932
- Estimated value
- $30,998
- Report date
- 30 Jun 2022
- Price
- $0.3300
- Ownership
- Direct
Form 4 holding
Director
Rubius Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 499,762
- Estimated value
- Report date
- 12 May 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Senti Biosciences, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 125,000
- Estimated value
- Report date
- 13 Jul 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Evelo Biosciences, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- Report date
- 30 Jun 2022
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Opy Acquisition Corp. I
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 26 Oct 2021
- Price
- Ownership
- Direct
Form 4 holding
CEO, Director
Seagen Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- $229.00
- Ownership
- Direct
Form 4 holding
CEO, Director
Seagen Inc.
- Security class
- Performance Stock Units
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- $229.00
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
Form 4 holding
CEO, Director
Seagen Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- $229.00
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
Form 4 holding
CEO, Director
Seagen Inc.
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 14 Dec 2023
- Price
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
Insider Reports Filed by David R. Epstein
4
TEM
Tempus AI, Inc.
- Report period
- 03 Aug 2026
- Transactions
- 1
- Transaction value
- -$16,058
- Accepted by SEC
- 05 Aug 2026, 16:30
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 01 Jun 2026
- Transactions
- 1
- Transaction value
- -$12,350
- Accepted by SEC
- 03 Jun 2026, 16:28
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 21 May 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 26 May 2026, 21:45
- Role
- Director
- Next action
- Open filing details
3
AGMB
Agomab Therapeutics NV
- Report period
- 18 Mar 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Mar 2026, 16:01
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 02 Mar 2026
- Transactions
- 1
- Transaction value
- -$12,672
- Accepted by SEC
- 04 Mar 2026, 16:30
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 02 Feb 2026
- Transactions
- 1
- Transaction value
- -$21,982
- Accepted by SEC
- 04 Feb 2026, 16:30
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 01 Dec 2025
- Transactions
- 1
- Transaction value
- -$18,888
- Accepted by SEC
- 03 Dec 2025, 16:50
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 03 Nov 2025
- Transactions
- 1
- Transaction value
- -$33,300
- Accepted by SEC
- 05 Nov 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 02 Sep 2025
- Transactions
- 1
- Transaction value
- -$18,410
- Accepted by SEC
- 04 Sep 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 01 Aug 2025
- Transactions
- 1
- Transaction value
- -$20,409
- Accepted by SEC
- 05 Aug 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 02 Jun 2025
- Transactions
- 1
- Transaction value
- -$13,800
- Accepted by SEC
- 04 Jun 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 20 May 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 May 2025, 20:00
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 01 May 2025
- Transactions
- 1
- Transaction value
- -$19,795
- Accepted by SEC
- 05 May 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 17 Mar 2025
- Transactions
- 1
- Transaction value
- -$46,362
- Accepted by SEC
- 19 Mar 2025, 18:30
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 03 Mar 2025
- Transactions
- 1
- Transaction value
- -$14,380
- Accepted by SEC
- 05 Mar 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 03 Feb 2025
- Transactions
- 1
- Transaction value
- -$19,725
- Accepted by SEC
- 05 Feb 2025, 18:06
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 11 Dec 2024
- Transactions
- 1
- Transaction value
- -$25,922
- Accepted by SEC
- 13 Dec 2024, 18:20
- Role
- Director
- Next action
- Open filing details
4
TEM
Tempus AI, Inc.
- Report period
- 13 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2024, 21:45
- Role
- Director
- Next action
- Open filing details
3
TEM
Tempus AI, Inc.
- Report period
- 13 Jun 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2024, 18:40
- Role
- Director
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 14 Dec 2023
- Transactions
- 12
- Transaction value
- -$3,757,203
- Accepted by SEC
- 15 Dec 2023, 18:29
- Role
- CEO, Director
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 10 Nov 2023
- Transactions
- 1
- Transaction value
- -$2,262,166
- Accepted by SEC
- 13 Nov 2023, 20:02
- Role
- CEO, Director
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 15 Aug 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Aug 2023, 21:14
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
Seagen Inc.
- Report period
- 09 Nov 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 14 Nov 2022, 16:45
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
3
Seagen Inc.
- Report period
- 09 Nov 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 10 Nov 2022, 18:39
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
SNTI
Senti Biosciences, Inc.
- Report period
- 13 Jul 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Jul 2022, 18:00
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 30 Jun 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 30 Jun 2022, 16:52
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 10 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 16:41
- Role
- Director
- Next action
- Open filing details
4
SNTI
Dynamics Special Purpose Corp.
- Report period
- 08 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 21:22
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 31 May 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 01 Jun 2022, 16:12
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 27 May 2022
- Transactions
- 1
- Transaction value
- +$25,000
- Accepted by SEC
- 31 May 2022, 16:07
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 19 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2022, 16:30
- Role
- Director
- Next action
- Open filing details
4
Rubius Therapeutics, Inc.
- Report period
- 12 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 May 2022, 16:20
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 02 May 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 02 May 2022, 16:03
- Role
- Director
- Next action
- Open filing details
4
Rubius Therapeutics, Inc.
- Report period
- 21 Apr 2022
- Transactions
- 1
- Transaction value
- +$43,329
- Accepted by SEC
- 22 Apr 2022, 18:07
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 31 Mar 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 01 Apr 2022, 16:05
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 17 Mar 2022
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 21 Mar 2022, 16:30
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 16 Mar 2022
- Transactions
- 1
- Transaction value
- +$50,000
- Accepted by SEC
- 18 Mar 2022, 08:30
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 28 Feb 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 01 Mar 2022, 15:07
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 Feb 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 23 Feb 2022, 15:19
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 31 Jan 2022
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 31 Jan 2022, 16:06
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 Jan 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jan 2022, 15:30
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 31 Dec 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2022, 15:23
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 17 Dec 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Dec 2021, 15:15
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 30 Nov 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 01 Dec 2021, 15:39
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 Nov 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 22 Nov 2021, 17:04
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 01 Nov 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 01 Nov 2021, 17:22
- Role
- Director
- Next action
- Open filing details
3
Opy Acquisition Corp. I
- Report period
- 26 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 26 Oct 2021, 20:57
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 Oct 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 19 Oct 2021, 16:31
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 01 Oct 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 01 Oct 2021, 16:42
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 17 Sep 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Sep 2021, 16:31
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 03 Sep 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 03 Sep 2021, 16:55
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 Aug 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 19 Aug 2021, 16:15
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 16 Jul 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 Jul 2021, 16:31
- Role
- Director
- Next action
- Open filing details
4
Evelo Biosciences, Inc.
- Report period
- 30 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2021, 16:25
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2021, 17:42
- Role
- Director
- Next action
- Open filing details
3
SNTI
Dynamics Special Purpose Corp.
- Report period
- 25 May 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 25 May 2021, 20:21
- Role
- Director
- Next action
- Open filing details
4
Axcella Health Inc.
- Report period
- 18 May 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 May 2021, 16:31
- Role
- Director
- Next action
- Open filing details
4
Rubius Therapeutics, Inc.
- Report period
- 12 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 May 2021, 20:35
- Role
- Director
- Next action
- Open filing details